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ABSTRACT Extensive antigenic diversity within the GII.4 genotype of human noro-
virus is a major driver of pandemic emergence and a signiﬁcant obstacle to develop-
ment of cross-protective immunity after natural infection and vaccination. However,
human and mouse monoclonal antibody studies indicate that, although rare, anti-
bodies to conserved GII.4 blockade epitopes are generated. The mechanisms by
which these epitopes evade immune surveillance are uncertain. Here, we developed
a new approach for identifying conserved GII.4 norovirus epitopes. Utilizing a unique
set of virus-like particles (VLPs) representing the in vivo-evolved sequence diversity
within an immunocompromised person, we identify key residues within epitope F, a
conserved GII.4 blockade antibody epitope. The residues critical for antibody binding
are proximal to evolving blockade epitope E. Like epitope F, antibody blockade of
epitope E was temperature sensitive, indicating that particle conformation regulates
antibody access not only to the conserved GII.4 blockade epitope F but also to the
evolving epitope E. These data highlight novel GII.4 mechanisms to protect blockade
antibody epitopes, map essential residues of a GII.4 conserved epitope, and expand
our understanding of how viral particle dynamics may drive antigenicity and
antibody-mediated protection by effectively shielding blockade epitopes. Our data
support the notion that GII.4 particle breathing may well represent a major mecha-
nism of humoral immune evasion supporting cyclic pandemic virus persistence and
spread in human populations.
IMPORTANCE In this study, we use norovirus virus-like particles to identify key resi-
dues of a conserved GII.4 blockade antibody epitope. Further, we identify an addi-
tional GII.4 blockade antibody epitope to be occluded, with antibody access gov-
erned by temperature and particle dynamics. These ﬁndings provide additional
support for particle conformation-based presentation of binding residues mediated
by a particle “breathing core.” Together, these data suggest that limiting antibody
access to blockade antibody epitopes may be a frequent mechanism of immune
evasion for GII.4 human noroviruses. Mapping blockade antibody epitopes, the inter-
action between adjacent epitopes on the particle, and the breathing core that medi-
ates antibody access to epitopes provides greater mechanistic understanding of
epitope camouﬂage strategies utilized by human viral pathogens to evade immu-
nity.
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Antigenic diversity is a hallmark of many successful RNA viruses. However, require-ments for structure integrity and maintenance of key capsid functions such as
receptor binding and cell fusion require essential residues to remain conserved over
time, representing potential cross-protective antibody (Ab) epitopes (1–3). To combat
this weakness, many human RNA viruses, including seasonal inﬂuenza virus (4), human
immunodeﬁciency virus (5), hepatitis C virus (6), Ebola virus (7), West Nile virus (8), and
human norovirus (9), have evolved strategies to camouﬂage neutralizing antigenic
sites. Local mechanisms of camouﬂage include shielding of the epitope with carbohy-
drates (4, 10) or lipids (11, 12) or by structurally occluding the site by burying the
epitopes beneath the surface topology (6, 13–15). Other mechanisms include “particle
breathing,” described as dynamic conformational changes in the virion that limit
antibody access to occluded epitopes (5, 7–9, 16, 17). Effective use of these evasive
mechanisms provides an advantage to viruses with high population exposure, includ-
ing human norovirus.
Human norovirus is the leading cause of acute gastroenteritis, causing more than 21
million infections per year in the United States and approximately 200,000 deaths
worldwide, primarily in the young and aged populations (18). This heavy disease
burden on particularly vulnerable populations warrants development of a norovirus
vaccine. The primary obstacle to a successful vaccine is the extensive antigenic diversity
between norovirus strains and within the pandemic GII.4 strains (19–21). Like inﬂuenza
A virus, the major capsid sequence of the norovirus GII.4 strains is undergoing epochal
evolution, resulting in emergent immune escape variants every 2 to 5 years (20, 22, 23).
Using an in vitro surrogate neutralization assay to measure antibody blockade of
norovirus virus-like particle (VLP) binding to carbohydrate ligand, shown to correlate
with protection from infection, four evolving “blockade” antibody epitopes have been
characterized (24, 25). Epitope A is immunodominant (~40% of the serum blockade
antibody response) and changes with each epidemiologically signiﬁcant strain (26–28).
Epitope D lies along the ridge of the carbohydrate-binding domain and is both a
blockade antibody epitope and a mediator of carbohydrate binding afﬁnities (25).
Epitopes A and D face the most exterior part of the viral particle (the P2 subdomain)
and are easily accessible to potent blockade antibodies (9). Epitope E is lateral to
epitope D and is less exposed to the surface (25, 29). Finally, epitope F is highly
conserved across GII.4 strains, and its structural location is unknown (9, 25). Norovirus
infection and vaccination elicit antibodies to subdominant epitope F. Antibody
binding to epitope F is mediated by residues outside the antibody-binding site.
Residues 310, 316, 484, and 493, the NERK motif, are highly conserved across GII.4
strains (9) and are located distal to the top surface of the particle where epitopes
A and D are located. Incubation temperature and mutations in the NERK motif affect
antibody access to epitope F by allosteric effects on particle conformation with an
unclear mechanism (25, 30).
The goal of this study is to identify the GII.4 conserved blockade epitope recognized
by human monoclonal antibody (MAb) GII.4F. The high degree of conservation of
epitope F has limited the effectiveness of bioinformatic approaches to identifying
epitope F and additional NERK motif residues, although this approach was instrumental
to predicting evolving blockade antibody epitopes that were further veriﬁed by testing
chimeric VLPs and MAbs (25, 26). Here, we used a unique set of reagents based on viral
sequences isolated from an immunocompromised person with a long-term norovirus
infection (31, 32) to identify key residues of a conserved GII.4 blockade antibody
epitope. These residues were invariant in all other panels of GII.4 VLPs that we have
studied thus far. In addition, we apply quantitative biochemical analyses to differentiate
between residues that affect antibody binding (epitope) and residues that affect
antibody access to the epitope through allosteric mechanisms (particle dynamics
regulating domain). These ﬁndings provide new support for particle conformation-
based presentation of key binding residues that are regulated by a “breathing core”
which includes the NERK motif and an additional amino acid. Further, like epitope F,
epitope E is demonstrated to be occluded, with Ab access governed by temperature
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and particle dynamics. These data indicate that limiting antibody access to blockade
antibody epitopes may be a frequent mechanism of immune evasion for GII.4 human
noroviruses. Mapping a blockade antibody epitope, the interaction between adjacent
epitopes on the particle, and the breathing core that mediates antibody access to
epitopes provides greater mechanistic understanding of epitope camouﬂage strategies
utilized by human viral pathogens.
RESULTS
Residues 327 and 404 are key binding sites of the GII.4 conserved blockade
antibody epitope. GII.4F or GII.4G MAbs recognize two spatially close conserved
blockade epitopes with restricted access based on particle conformation (9). The spatial
locations of targeted residues (Table 1) remain unknown, although NERK motif modi-
ﬁcations in part regulate access to these epitopes (9). To map GII.4F or GII.4G residues,
VLPs representing time-ordered GII.4.2006a norovirus strains that evolved within an
immunocompromised transplant patient over 683 days (31, 32) were synthesized,
expressed, and characterized for binding of GII.4F or GII.4G MAbs by enzyme immu-
noassay (EIA) (Fig. 1). GII.4G MAb appears to bind to a unique conserved epitope,
designated epitope G, that may overlap epitope F and was preserved during the period
of monitoring, as assessed by both binding and blockade assays. In contrast, by day
TABLE 1 Characteristics of monoclonal antibodies used in this study
MAb Synonym(s) Species Immunogen Epitope
GII.4E GII.4.2002.G6 Mouse GII.4.2002 Variable, blockade
epitope E of GII.4.2002
GII.4F NVB 71.4 Human Natural infection Conserved GII.4, blockade,
conformation dependent,
epitope F
GII.4G GII.4.2002.G5,
MAB227P
Mouse GII.4.2002 Conserved GII.4, blockade,
conformation dependent,
epitope G
FIG 1 Long-term in vivo evolution results in loss of GII.4 epitope F, a conserved GII.4 blockade antibody
epitope. (A) Virus-like particles representing norovirus sequences isolated from an immunocompromised
transplant patient over a 683-day period were evaluated for binding to MAbs GII.4F and GII.4G by enzyme
immunoassay. Both MAbs recognize conserved GII.4 blockade epitopes that overlap each other and are
occluded by structural conformation. Error bars represent 95% conﬁdence intervals. Values that are
signiﬁcantly different (P  0.05) from the day 1 value are indicated by an asterisk. (B) After a minimum of
581 days of in vivo evolution, capsid sequence changes, indicated by color changes, resulted in loss of
binding of human MAb GII.4F but not mouse MAb GII.4G.
Human Norovirus Epitope Shielding
January/February 2018 Volume 3 Issue 1 e00518-17 msphere.asm.org 3
 o
n
 N
ovem
ber 26, 2018 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
581, evolution in epitope F resulted in loss of binding of MAb GII.4F (Fig. 1A). Day 581
VLP is the ﬁrst identiﬁed GII.4 VLP not to react with MAb GII.4F. Amino acid substitu-
tions associated with in vivo evolution occurred at 22 residues within the major capsid
protein between day 1 and 581 of monitoring (31). Fifteen of the changed residues
were in the P2 domain, potentially inﬂuencing blockade antibody epitopes (Fig. 1B). To
map the epitope for MAb GII.4F, amino acid changes in the capsid protein were
compared, and sets of changes were introduced into the day 581 backbone sequence
(Fig. 2). Restoring the 14 residues in 581.F2 resulted in an increase in the binding of
GII.4F similar to the increase from restoring all 22 residues that differed between day 1
and day 581 (581.Day1) (Fig. 2A). 581.F3 and F4, but not 581.F1, improved GII.4F
binding in EIA. A ﬁve-residue exchange of F2 residues (residues 234, 327, 340, 391, and
404) into the day 581 backbone (581.FX) resulted in an increase in GII.4F binding and
was further analyzed (Fig. 2B and C). Only VLPs with valines at positions 327 and 404
were sufﬁcient to restore GII.4F binding (581.F). Conversely, when changing V327 to K
and V404 to E in GII.4.2002 (2002.581F), GII.4F binding was lost, conﬁrming that V327
and V404 are critical key residues of the conserved GII.4 blockade Ab epitope F.
Homology modeling of residues 327 and 404 shows that they form a conformational
epitope proximal to evolving blockade antibody epitope E. In the model, K327 directly
FIG 2 Residues 327 and 404 are key binding sites for GII.4F MAb. (A and B) To map the epitope for the GII.4F MAb, amino
acid changes in the capsid protein between day 1 and day 581 strains were compared and sets of changes were introduced
into the 581 backbone sequence. Chimeric VLPs were evaluated for MAb binding by EIA, and EC50 titers were determined.
Values signiﬁcantly different (P  0.05) from 581.Day1 (A) or 581.FX (B) are noted with an asterisk. (C) Residues that were
changed are shown in color to indicate gain (green) or loss (red) of GII.4F MAb binding. Changing valine at residues 327
and 404 resulted in an increase in binding of GII.4F MAb to 581 (581.F), while replacing valine at residues 327 and 404 in
GII.4.2002 (2002.581F) resulted in a loss of binding of the GII.4F MAb.
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interacts with E404 via electrostatic interaction, which likely rearranges the local
structural neighborhood of epitope F. In addition, modeling of the hydrogen bond
networks between residues V327, Q401, and V404 suggests that three hydrogen bonds
are formed in the day 262 isolate (Fig. 3, red dashed lines), while two additional
hydrogen bonds (blue dashed lines) are formed in the day 581 model among 327K,
401Q, and 404E. These additional bonds likely contribute to the loss of GII.4F binding
to day 581 VLPs.
Residue 234 inﬂuences GII.4F MAb access to the conserved blockade antibody
epitope. As previously described, GII.4F MAb blockade potency is mediated by both
the number of accessible binding sites as well as by the afﬁnity of the antibody for the
target epitope (9). To understand the contributions to binding of the ﬁve residues
included in 581.FX, chimeric VLPs containing admixtures of residues 234, 327, 340, 391,
and 404 (581.F9-F12) were tested for GII.4F MAb binding by EIA (9, 33). VLPs are
composed of 90 copies of a dimer of the capsid protein, accounting for a total of 180
copies of nonquaternary epitopes. Changes in the maximum number of binding sites
(Bmax) reﬂect access to binding of antibody to the these epitopes (34). Kd (dissociation
constant, relative afﬁnity) is dependent on the strength of molecular interaction
between the epitope and the antibody. Changes in residues 340 and 391 did not affect
GII.4F MAb relative afﬁnity or access (Fig. 4). The Kd was consistent between the VLPs
with valines at positions 327 and 404 (1.1 nM), indicating that these residues deﬁne part
of GII.4 epitope F. V234 was not associated with changes in Kd. The V234 VLPs (581.FX
and 581.F12) (Fig. 4) had higher Bmaxs than 581.F (K327V and E404V), indicating that
residue 234 may be inﬂuencing GII.4F MAb binding via long-range allosteric effects,
as described for the NERK motif (9). The NERK motif and residue 234 (the “breathing
core”) are distal to the epitope and near the dimer interface (Fig. 5).
Antibody access to evolving blockade antibody epitope E depends on global
particle and local conformation. Epitope E, like epitope F, is lateral to epitopes A and
D, which line the outermost surface of the viral particle (25). Epitope E and F residues
are within 7 to 23 Å of each other. To determine whether particle conformation also
regulates antibody access to epitope E, GII.4.2002 blockade by MAb GII.4E (Table 1) (29)
was tested at room temperature and 37°C, as previously described (Fig. 6) (9). Increased
temperature of incubation resulted in a 2.7-fold decrease in 50% effective concentra-
tion (EC50) titer and a 3.2-fold increase in blockade curve slope for GII.4E blockade of
GII.4.2002 (Fig. 6A), indicating that GII.4E access to evolving blockade epitope E
improves at higher temperature. These results are similar to those reported for epitope
F and G blockade and suggest that particle dynamics also regulate antibody access to
epitope E (9).
To explore any direct or indirect interaction between epitopes E and F, a series of
VLPs with exchanged epitope E, epitope F, or both were tested for EIA binding with
FIG 3 Homology models of epitope F interactions between days 262 and 581 viruses. (A) Amino acid positions 327,
401, and 404 are shown in green on the P2 dimer for context. (B and C) Three hydrogen bonds (red dashed lines)
are evident among residues 327V, 401Q, and 404V in the day 262 model (B), while the original three hydrogen
bonds (red dashed lines) plus two additional hydrogen bonds (blue dashed lines) are formed in the day 581 model
(C) among 327K, 401Q, and 404E.
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MAb GII.4E (Fig. 6B). Exchange of either epitope E (581.2002E) or F (581F) residues from
GII.4.2002 into the 581 backbone did not confer GII.4E binding. However, exchange of
both epitopes E and F (581.2002E/F) resulted in an increase in GII.4E binding. Con-
versely, exchange of epitope F residues from 581 into the 2002 (2002.581F) backbone
increased 2.9-fold the EC50 titer of GII.4E for GII.4.2002. These data indicate that epitope
F residues affect the binding of epitope E antibodies. To distinguish the effects of
epitope E and F residues on GII.4E binding, chimeric VLPs were tested for GII.4E binding
by EIA, and Bmax and Kd values were calculated (Fig. 6C). Exchange of day 581 epitope
FIG 4 GII.4F antibody access to epitope F is inﬂuenced by residue 234, a residue outside the epitope.
GII.4F MAb EC50 titer is mediated by both the maximum number of binding sites available (Bmax) and the
relative afﬁnity of the antibody for the epitope. To distinguish the effects of the ﬁve residues comprising
581.FX, chimeric VLPs containing admixtures of residues (orange) were tested for GII.4F MAb binding by
EIA, and Bmax and Kd values were calculated. Changes in residues 340 and 391 did not change GII.4F MAb
binding or access (red). The Kd for the epitope was consistent between the VLPs with valine at positions
327 and 404, identifying these residues as part of the GII.4 epitope F (green). In comparison, 234V was
not associated with changes in Kd (red). The 234V VLPs had higher Bmax values than the 581.F VLPs,
indicating that residue 234 may be inﬂuencing GII.4F MAb binding via long-range allosteric effects, as
described for the NERK motif. Bold values are signiﬁcantly different (P  0.05) from the values for 581.F.
LOD, less than the limit of detection.
FIG 5 Residues important for mediating GII.4 norovirus antigenicity. A homology model of a P2 domain
dimer (light gray and magenta monomers) of GII.4.2006a bound to A antigen (red and green) with
identiﬁed blockade antibody epitopes A (blue), D (black), E (orange), and F (purple) and the “breathing
core” residues (NERK plus residue 234) that mediate global particle conformation (yellow) color coded.
The full GII.10 VLP, in which P dimers are shown in gray, is shown for context.
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F residues into the 2002 backbone (2002.581F) did not change the Kd (0.33 nM) for
GII.4E but did decrease the Bmax. Therefore, epitope F residues are not part of epitope
E but instead regulate GII.4E epitope access. These data indicate that local particle
conformation also regulates antibody access to blockade epitopes.
DISCUSSION
Blockade antibody responses are proposed correlates of human norovirus protective
immunity (35). Elucidation of the speciﬁc epitopes correlated with protection could
facilitate vaccine design strategies (36, 37). Human norovirus infection elicits a skewed
blockade antibody response to the hypervariable epitope A of the infecting strain (9,
26). Similarly, in human trials, norovirus multivalent VLP vaccination recalls a memory
response to previous strain epitope A (30). The ability to harness preferential antigen
presentation on VLP vaccines could selectively drive vaccine immune responses away
from the hypervariable epitopes and toward cross-protective conserved epitopes (10,
38). This report is the ﬁrst to map key amino acids comprising part of a conserved GII.4
FIG 6 GII.4E MAb binding is regulated by global particle conformation and surrounding local topology. (A) GII.4.2002 VLP
binding to ligand was blocked by GII.4E at either room temperature (black) or 37°C (red), and mean percent control binding
compared to no antibody was ﬁt by sigmoidal dose-response curve analysis, with the Hill slopes and EC50s calculated.
Incubation at 37°C resulted in a steeper curve and lower EC50 titer, indicating that antibody access to epitope E is
dependent upon particle conformation, as described for epitopes F and G. (B) Exchange of both epitope E and F residues
into the 581 backbone (581.2002E/F) improved binding of GII.4E MAb compared to exchanging only either epitope E
(581.2002E) or epitope F (581.F) residues. Values that are signiﬁcantly different (P  0.05) from the value for 581.2002E/F
are indicated by an asterisk. (C) To distinguish the effects of epitope E and F residues on GII.4E binding, chimeric VLPs
(orange) were tested for GII.4E binding by EIA, and Bmax and Kd values were calculated. Exchange of day 581 epitope F
residues into the 2002 backbone (2002.581F) did not change the Kd for GII.4E but did decrease the Bmax, indicating that
epitope F residues mediate GII.4E epitope access. In support of this hypothesis, exchange of both epitope E and F residues
from the 2002 backbone into the 581 backbone (581.2002E/F) was necessary to restore GII.4E binding. Bold values are
signiﬁcantly different (P  0.05) from GII.4.2002. Green shading indicates residues involved in GII.4E epitope binding and
access to the epitope. LOD, less than the limit of detection.
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norovirus blockade antibody epitope (epitope F) recognized by a human monoclonal
antibody, identify two additional conformation-dependent epitopes (epitopes E and G),
and expand the set of residues that inﬂuence particle dynamics and antibody access to
occluded blockade antibody epitopes. These are important steps in designing an
engineered cross-protective norovirus VLP vaccine candidate.
The implications of norovirus infection in immunocompromised individuals is an
expanding area of study. Virus sequencing from serial stool samples indicates that even
under the atypical (reduced) immune pressure exerted in an immunocompromised
patient, norovirus continues to evolve via antigenic drift at blockade antibody epitopes
(Fig. 1) (32). This process mimics viral evolution within the general population that leads
to the emergence of new viruses (20, 23). An extended period of in vivo evolution
allowed the ﬁrst identiﬁed change in epitope F. Valine at positions 327 and 404 are part
of epitope F and are conserved across GII.4 norovirus strains circulating from 1974 to
2015. Occluded epitopes of other human RNA viruses are essential for receptor binding,
viral fusion, and capsid assembly/disassembly, functions essential for infection/replica-
tion (1–3). It is unknown whether particle conformation plays similar roles in the
norovirus life cycle or whether antibody binding to epitope F affects particle dynamics
necessary for ligand binding or sterically blocks ligand interaction. The primary limita-
tion to this study is the lack of a reverse genetics system to test these possibilities. The
newly developed human norovirus replication system (39) may someday be amenable
to a reverse genetics approach to studying viral mutants and elucidate the roles of
epitope F residues. It is possible that V327 and V404 are not part of epitope F, but
instead, mutations at these residues such as those observed in this study could prevent
conformational transitions necessary for antibody binding. However, this explanation is
unlikely, as antibody access to the overlapping epitope G and the neighboring epitope
E remains temperature sensitive, indicating that particle plasticity is maintained in the
581 VLP (327K.404E).
Unlike residues 327 and 404, residue 234 is buried near the dimer interface and does
not participate in GII.4F binding. Instead, residue 234 regulates antibody access to
occluded epitopes by mediating particle conformation, similarly to what has been
described for residues 310, 316, 484, and 493 (NERK motif) (9). These data indicate that
residue 234, the NERK motif, and possibly other unidentiﬁed amino acids form a
“breathing core” that works in concert to regulate global particle structure driving
antigenicity and ligand binding (Fig. 5). Similarly, recent detailed bioinformatic studies
with a monoclonal antibody with broad mouse norovirus neutralization potency iden-
tiﬁed a single amino acid outside the antibody-binding site that mediated antibody
binding by changing particle conformation (40). A mutation distal to the surface altered
interfacial interactions between the P domains of the dimers affecting the structure
throughout the P domain. These data support previous ﬁndings on the NERK motif on
human norovirus particle dynamics and the allosteric effect distant residues can have
on antibody binding and suggest conformation-based epitope camouﬂage may be a
mechanism of immune evasion conserved across noroviruses. Mutations in the breath-
ing core could modulate epitope presentation, altering the effectiveness of antibody
responses in protection from infection and inﬂuencing the repertoire of antibodies
made following vaccination and infection (38). The NERK motif is highly conserved in
GII.4 strains from 1974 to 2006. Contemporary strains GII.4.2009 and 2012 both intro-
duced mutation at residue 310, which resulted in altered antibody access to epitope F
(9). Although speculative, changes at residue 310 may have been driven by pressure to
alter protection of epitope F. Further, controlling particle dynamics may have practical
implications for VLP immunogens where viral entry is not maintained. An engineered
VLP designed to have decreased ﬂuctuation by temperature could improve thermo-
stability and shelf life of VLP-based vaccines (41), as well as enhance antigen presen-
tation stability (42).
On the basis of our existing panels of antibodies, presentation of epitopes A and D
is not dependent on the particle conformation and changes in the NERK motif do not
affect blockade potency of antibodies to these epitopes (9). The ﬁndings presented
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here indicate that the delineating factor between occluded and nonoccluded epitopes
is likely location on the viral particle. Evolving blockade epitope E lies near the
transition from the most-surface-exposed P2 subdomain of the capsid protein and the
less-surface-exposed P1 subdomain. Epitope E is variable between pandemic strains,
and antibody access is occluded (25, 29). Although a virion has the same number of
epitopes A, E, F, and G, antibodies to epitopes E, F, and G are rare, compared to epitope
A. Only a single monoclonal antibody to each epitope has been characterized thus far
(25, 29), possibly reﬂecting immune suppression mechanisms that inﬂuence the anti-
genicity of these epitopes. The coordinates of epitope G are unknown, but like epitope
E, are nearby and/or overlapping with epitope F (9). Mutation in the breathing core and
temperature sensitivity of antibody blockade indicate that antibody access to epitopes
E, F, and G is mediated at the global particle level. The observation that exchange of
both epitope E and F residues from the 2002 backbone into the 581 backbone
(581.2002E/F), but not epitope E residues alone, was necessary to increase GII.4E
binding, indicates that antibody access is also mediated at the local level by the
conformation of surrounding residues (43). These conformation-dependent regulatory
mechanisms are likely to extend to other epitopes within the P1 subdomain. Additional
human monoclonal antibodies resulting from norovirus infection and vaccination are
needed to identify other epitope signatures and the interdependence of distinct
epitopes within a continuous antigen.
These studies expand our understanding of the complex mechanisms of human
norovirus immune evasion (Fig. 7) and persistence in human populations. In addition to
immune-driven selective pressure on a subset of residues to change (antigenic drift),
global particle structure (mediated by the distant breathing core residues) and local
FIG 7 Sequence and spatial ﬂexibility within the capsid of GII.4 noroviruses mitigates antibody-mediated
protective immunity. Three mechanisms of immune evasion are proposed here. First, antibody binding
to epitopes can be occluded by steric hindrance resulting from particle contraction during “breathing”
(epitopes E, F, and G). Second, antibody binding to epitopes can be occluded by steric hindrance
resulting from local particle conformation (epitopes E and F). Third, antigenic drift in highly antigenic,
surface-exposed epitopes (epitopes A, D, and E) can facilitate antibody escape over time.
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particle structure (mediated by closely surrounding residues) impact antibody access to
blockade epitopes. These topological changes effectively reduce antibody binding
without requiring changes in the residues that comprise the actual epitopes. These
structure conformation-based immune evasion strategies are particularly advantageous
for protecting essential conserved motifs that could be targeted by antibodies. Noro-
virus joins other successful human pathogens such as HIV (5), inﬂuenza virus (10), Ebola
virus (7), West Nile virus (8), and poliovirus (14) that use conformation-based shielding
of key essential residues to evade development of protective immunity. Further study
is needed to test the effects of breathing core mutations on presentation of epitopes
E, F, and G. Concurrent with modifying the breathing core to change epitope access,
surface residues that sterically block antibody access to the occluded epitopes may be
identiﬁed. Changing these surface residues may be an easier path to design a VLP
immunogen with preferential presentation of conserved epitopes and better cross-
reactivity with emergent GII.4 strains (6, 36), a primary goal for norovirus vaccinology.
These concepts that characterize how viral particle dynamics inﬂuence antigen presen-
tation and antibody access to blockade epitopes may be applicable to vaccine strate-
gies for other highly penetrant, antigenically diverse viruses.
MATERIALS AND METHODS
Virus-like particles. Synthetically derived (Bio Basic Inc., Amherst, NY) ORF2 genes were inserted
directly into the Venezuelan equine encephalitis replicon vector. Virus-like particles (VLPs) were ex-
pressed in baby hamster kidney cells (ATCC CCL-10TM) and puriﬁed by velocity sedimentation in sucrose
(44). VLP protein concentrations were determined by the BCA protein assay (Pierce, Rockford, IL). Uranyl
acetate-stained VLPs were visualized by transmission electron microscopy (see Fig. S1 in the supple-
mental material).
Enzyme immunoassay. The wells on enzyme immunoassay (EIA) plates were coated with 0.25 g/ml
VLP in phosphate-buffered saline (PBS) for 4 h and blocked overnight at 4°C in 5% dry milk in PBS
containing 0.05% Tween 20 (PBS–0.05% Tween 20) before the addition of decreasing twofold serial
dilutions of monoclonal antibody (MAb). Bound MAb was detected by anti-human or mouse IgG
conjugated to horseradish peroxidase (anti-human/mouse IgG-HRP) (GE Healthcare) and color developed
with 1-Step Ultra TMB ELISA HRP substrate solution (Thermo Fisher). Each step was followed by washing
with PBS–0.05% Tween 20, and all reagents were diluted in 5% dry milk in PBS–0.05% Tween 20. All
incubations were done at 37°C. To determine 50% effective concentrations (EC50s) for antibodies with
optical densities (ODs)  3 background at 2 g/ml, EIA data were log transformed and ﬁt using
sigmoidal dose-response analysis of nonlinear data in GraphPad Prism 7.02 (GraphPad Software, La Jolla,
CA) (9). Monoclonal Abs below the limit of detection were assigned an EC50 of 2 the assay upper limit
of detection for statistical comparison. EC50s between VLPs were compared using the one-way analysis
of variance (ANOVA) with Dunnett’s posttest. A difference was considered signiﬁcant if the P value was
0.05. Bmax and Kd values were estimated by one-site speciﬁc binding nonlinear curve ﬁt of mean OD
values in GraphPad Prism 7.02 (9, 33).
Antibody blockade of VLP binding assay (blockade). VLPs (0.25 g/ml) were pretreated with
decreasing concentrations of MAb for 1 h and added to wells coated with pig gastric mucin type III
(Sigma-Aldrich, St. Louis, MO) for 1 h. Bound VLP was detected as described above using anti-VLP rabbit
hyperimmune sera. Percent control binding is deﬁned as the level of binding in the presence of antibody
pretreatment compared to the level of binding in the absence of antibody multiplied by 100. The
blockade data were ﬁt using sigmoidal dose-response analysis of nonlinear data in GraphPad Prism 702.
EC50 and Hill slope values were calculated for antibodies that demonstrated blockade of at least 50% at
the dilution series tested. Antibodies that did not block 50% of binding at the highest dilution tested
were assigned an EC50 of two times the assay upper limit of detection for statistical comparison (9).
Increasing antibody-VLP-ligand incubations to 40°C (simulating fever) decreases the blockade EC50 about
twofold, or one dilution, in preliminary studies.
Structural modeling. Structural homology models representing the capsid P domain of GII.4.2006A
(GenBank accession number EF126964.1) and immunocompromised patient virus days 262 and 581 (31)
were generated using Swiss-Model. To do this, capsid amino acid sequences for these viruses were
uploaded into the Swiss-Model modeling server (https://swissmodel.expasy.org/interactive), and the
appropriate background template was chosen by clicking “search for templates” and then choosing the
known structure with the highest homology score. For all sequences, the chosen template was PDB
accession number 3SLD, which is the crystal structure for the GII.4.2004 capsid bound to A trisaccharide
(45). Models of the capsid dimers were created using the 3SLD template and downloaded in .pdb format.
Models were rendered using MacPymol version 1.8.0.4 (https://www.pymol.org/). Hydrogen bonds were
identiﬁed among speciﬁc amino acids by selecting those amino acids and using the “Action” command
to choose “ﬁnd,” then “polar contacts,” and then “within selection.” The distance in angstroms between
epitopes E and F was calculated using Pymol’s measurement tool. The low end of the range was
determined by measuring the distance between the closest residues within each epitope, and the high
end of the range was the distance between the furthest residues within each epitope. To generate the
full VLP image, the cryo-electron microscopy (cryo-EM) structure of GII.10 (EMD-5374) was downloaded
Lindesmith et al.
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from the Protein Data Bank in Europe (https://www.ebi.ac.uk/pdbe) and visualized in UCSF Chimera
(version 1.12). The contour level was set R 2.87 and colored using the “surface color” function.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00518-17.
FIG S1, TIF ﬁle, 2.7 MB.
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